| Literature DB >> 26393577 |
Ilzira A Minigalieva1, Boris A Katsnelson2, Larisa I Privalova3, Marina P Sutunkova4, Vladimir B Gurvich5, Vladimir Y Shur6, Ekaterina V Shishkina7, Irene E Valamina8, Oleg H Makeyev9, Vladimir G Panov10, Anatoly N Varaksin11, Ekaterina V Grigoryeva12, Ekaterina Y Meshtcheryakova13.
Abstract
Stable suspensions of NiO and Mn₃O₄ nanoparticles (NPs) with a mean (±s.d.) diameter of 16.7±8.2 and 18.4±5.4 nm, respectively, purposefully prepared by laser ablation of 99.99% pure nickel or manganese in de-ionized water, were repeatedly injected intraperitoneally (IP) to rats at a dose of 2.5 mg/kg 3 times a week up to 18 injections, either alone or in combination. A group of rats was injected with this combination with the background oral administration of a "bio-protective complex" (BPC) comprising pectin, vitamins A, C, E, glutamate, glycine, N-acetylcysteine, selenium, iodide and omega-3 PUFA, this composition having been chosen based on mechanistic considerations and previous experience. After the termination of injections, many functional and biochemical indices and histopathological features (with morphometric assessment) of the liver, spleen, kidneys and brain were evaluated for signs of toxicity. The Ni and Mn content of these organs was measured with the help of the atomic emission and electron paramagnetic resonance spectroscopies. We obtained blood leukocytes for performing the RAPD (Random Amplified Polymorphic DNA) test. Although both metallic NPs proved adversely bio-active in many respects considered in this study, Mn₃O₄-NPs were somewhat more noxious than NiO-NPs as concerns most of the non-specific toxicity manifestations and they induced more marked damage to neurons in the striatum and the hippocampus, which may be considered an experimental correlate of the manganese-induced Parkinsonism. The comparative solubility of the Mn₃O₄-NPs and NiO-NPs in a biological medium is discussed as one of the factors underlying the difference in their toxicokinetics and toxicities. The BPC has attenuated both the organ-systemic toxicity and the genotoxicity of Mn₃O₄-NPs in combination with NiO-NPs.Entities:
Keywords: bioprotectors; manganese(II, III) oxide; nanoparticles; nickel(II) oxide; subchronic toxicity
Mesh:
Substances:
Year: 2015 PMID: 26393577 PMCID: PMC4613324 DOI: 10.3390/ijms160922555
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Total manganese and nickel contents of rat’s organs, mcg per g of dried tissue, after repeated intraperitoneal injections of NiO or Mn3O4 nanoparticles, together or separately, and of their combination with background oral administration of the BPC (X ± s.e.).
| Metal | Groups of Rats Given (6 Rats) | ||||
|---|---|---|---|---|---|
| Control | NiO-NPs | Mn3O4-NPs | NiO-NPs + Mn3O4-NPs | NiO-NPs + Mn3O4-NPs and BPC | |
| Manganese | 7.33 ± 0.56 | 6.33 ± 0.49 | 7.20 ± 0.73 | 6.80 ± 0.20 | 7.17 ± 0.31 |
| Nickel | 3.17 ± 0.65 | 16.40 ± 3.26 *,+,○ | 2.80 ± 0.20 + | 38.00 ± 2.80 * | 18.50 ± 1.56 *,+ |
| Manganese | 28.80 ± 1.74 | 32.00 ± 4.15 | 25.00 ± 1.87 | 25.83 ± 4.23 | 14.00 ± 2.33 *,+ |
| Nickel | 25.60 ± 1.89 | 46.75 ± 8.44 * | 32.50 ± 4.63 | 36.17 ± 7.21 | 36.25 ± 8.97 |
| Manganese | 13.75 ± 0.95 | 10.00 ± 0.63 *,○ | 20.50 ± 1.45 *,+ | 10.80 ± 1.11 | 16.17 ± 1.62 + |
| Nickel | 18.20 ± 1.56 | 20.60 ± 3.23 | 16.00 ± 1.58 | 17.60 ± 1.29 | 18.67 ± 1.28 |
| Manganese | 6.00 ± 0.45 | 7.17 ± 0.98 | 10.75 ± 1.70 * | 7.60 ± 1.08 | 9.20 ± 0.80 * |
| Nickel | 14.67 ± 0.96 | 12.83 ± 1.20 | 15.75 ± 2.46 | 15.80 ± 2.65 | 8.60 ± 0.60 + |
* statistically significant difference from the control group; + from the group given NiO-NPs + Mn3O4-NPs (without the BPC); ○ from the group given Mn3O4-NPs; (p < 0.05 by Student’s t-test with Bonferroni correction).
Figure 1Nickel (as NiO-NPs) content of the liver and spleen in the groups of rats exposed to NiO-NPs, to Mn3O4-NPs + NiO-NPs, or to the same combination together with the BPC (designated as NiO-NPs, Mn + Ni and Me + BPC, respectively). Electron paramagnetic resonance (EPR) method. Dots correspond to arithmetic means; bars, to 95% CI.
Total manganese and nickel renal excretion in rats after repeated intraperitoneal injections of NiO or Mn3O4 nanoparticles, together or separately, and of their combination with background oral administration of the BPC, mcg per 24 h (X ± s.e.).
| Metal | Groups of Rats Given | |||||
|---|---|---|---|---|---|---|
| Control (7 Rats) | NiO-NPs (8 Rats) | Mn3O4-NPs (8 Rats) | NiO-NPs + Mn3O4-NPs (7 Rats) | NiO-NPs + Mn3O4-NPs and BPC (7 Rats) | BPC (7 Rats) | |
| Manganese | 0.06 ± 0.05 | 0.008 ± 0.006 + | 0.06 ± 0.01 + | 0.52 ± 0.1 * | 0.28 ± 0.1 | 0.11 ± 0.1 |
| Nickel | 2.9 ± 0.2 | 37.9 ± 5.3 *,+,○ | 0.63 ± 0.3 *,+ | 16.7 ± 2.9 * | 40.8 ± 6.2 *,+ | 3.2 ± 0.3 |
* statistically significant difference from the control group; + from the group given NiO-NPs + Mn3O4-NPs (without the BPC); ○ from the group given Mn3O4-NPs; (p < 0.05 by Student’s t-test with Bonferroni correction).
Some functional indices for the condition of rat after repeated intraperitoneal injections of NiO or Mn3O4 nanoparticles separately and of their combination with background oral administration of the BPC (X ± s.e.).
| Index | Control (10 Rats) | Mn3O4-NPs (11 Rats) | NiO-NPs (11 Rats) | NiO-NPs + Mn3O4-NPs (12 Rats) | NiO-NPs + Mn3O4-NPs and BPC (12 Rats) | BPC (10 Rats) |
|---|---|---|---|---|---|---|
| Starting body mass, g | 195.0 ± 4.8 | 207.3 ± 4.9 | 201.0 ± 3.0 | 203.2 ± 3.0 | 200.0 ± 5.9 | 204.5 ± 5.4 |
| Final body mass, g | 232.5 ± 5.5 | 243.2 ± 4.6 | 244.0 ± 2.9 | 247.3 ± 6.6 | 238.6 ± 7.6 | 239.5 ± 5.5 |
| Body mass gain, % | 19.4 ± 2.1 | 17.5 ± 1.4 | 21.5 ± 1.3 | 21.6 ± 2.0 | 19.4 ± 2.3 | 17.3 ± 1.4 |
| Liver mass, g per 100 g body mass | 3.5 ± 0.1 | 4.8 ± 0.1 *,+ | 4.0 ± 0.1 *,○ | 3.9 ± 0.1 | 3.7 ± 0.2 | 3.7 ± 0.2 |
| Spleen mass, g per 100 g body mass | 0.36 ± 0.01 | 0.48 ± 0.03 * | 0.41 ± 0.02 | 0.44 ± 0.03 * | 0.37 ± 0.03 | 0.38 ± 0.02 |
| Kidney mass, g per 100 g body mass | 0.64 ± 0.01 | 0.62 ± 0.02 * | 0.59 ± 0.01 * | 0.59 ± 0.01 * | 0.58 ± 0.01 | 0.64 ± 0.02 |
| Brain mass, g per 100 g body mass | 0.76 ± 0.01 | 0.72 ± 0.01 * | 0.72 ± 0.02 | 0.7 ± 0.02 | 0.68 ± 0.02 | 0.77 ± 0.02 |
| Temporal summation of sub-threshold impulses, s. | 15.9 ± 0.6 | 17.2 ± 1.03 | 17.6 ± 1.03 | 16.7 ± 1.0 | 16.9 ± 0.9 | 16.9 ± 1.1 |
| Number of head-dips into holes during 3 min | 9.2 ± 0.9 | 2.3 ± 0.6 *,+ | 5.3 ± 1.1 *,○ | 6.0 ± 1.0 * | 3.3 ± 1.4 * | 5.4 ± 1.5 |
| Hemoglobin, g/dL | 14.0 ± 0.4 | 13.0 ± 0.4 | 12.6 ± 0.2 * | 12.0 ± 0.8 * | 13.0 ± 0.4 | 13.8 ± 0.2 |
| Erythrocytes, 1012 cells/L | 7.8 ± 0.2 | 5.8 ± 0.2 * | 5.8 ± 0.2 * | 5.6 ± 0.4 * | 6.2 ± 0.2 | 6.4 ± 0.2 |
| Average volume of red blood cells, µm3 | 61.5 ± 1.0 | 65.9 ± 1.0 * | 64.6 ± 1.0 * | 64.9 ± 1.0 * | 61.8 ± 0.9 + | 65.9 ± 0.8 * |
| Hematocrit, % | 42.6 ± 0.6 | 38.4 ± 1.2 * | 37.8 ± 1.0 * | 36.6 ± 1.0 * | 39.4 ± 1.0 | 41.4 ± 1.0 |
| Reticulocytes, ‰ | 21.4 ± 3.1 | 25.2 ± 3.7 | 31.1 ± 3.1 * | 27.3 ± 3.0 | 21.5 ± 2.3 | 17.5 ± 2.3 |
| Leukocytes, 103/µL | 8.6 ± 0.8 | 10.4 ± 0.6 | 8.4 ± 0.8 + | 12.2 ± 1.0* | 11.4 ± 1.2 + | 8.6 ± 0.8 |
| Thrombocytes, 103/µL | 735.2 ± 37.6 | 771.6 ± 41.0 | 718.2 ± 36.8 | 802.6 ± 30.2 | 776.4 ± 39.8 | 751.4 ± 36.0 |
| Lymphocytes,% | 93.7 ± 1.0 | 84.5 ± 2.0 *,+ | 85.6 ± 2.3 * | 90.5 ± 1.5 | 91.3 ± 1.2 | 93.2 ± 0.8 |
| Monocytes,% | 4.9 ± 0.9 | 12.2 ± 1.6 *,+ | 11.1 ± 2.0 * | 7.7 ± 1.3 | 7.2 ± 0.9 | 5.4 ± 0.7 |
| Granulocytes,% | 1.3 ± 0.2 | 3.3 ± 0.6 *,+ | 3.2 ± 0.4 *,+ | 1.8 ± 0.3 | 1.6 ± 0.2 | 1.4 ± 0.3 |
| Bilirubin in blood serum, μmol/L | 2.02 ± 0.4 | 0.97 ± 0.1 * | 1.15 ± 0.1 * | 1.15 ± 0.1 * | 1.5 ± 0.1 + | 1.7 ± 0.1 |
| Succinate dehydrogenase (SDH) activity, number of formazane granules per 50 lymphocytes | 647.1 ± 14.5 | 551.6 ± 20.6 * | 560.7 ± 11.5 * | 530.2 ± 22.5 * | 569.1 ± 17.6 | 591.0 ± 11.5 * |
| Total protein content of blood serum, g/L | 76.0 ± 1.3 | 75.2 ± 1.7+ | 71.2 ± 1.7 * | 69.4 ± 1.9 * | 72.7 ± 1.2 | 79.4 ± 1.5 |
| Albumin content of blood serum, g/L | 46.6 ± 0.8 | 38.3 ± 0.9 * | 42.5 ± 1.1 *,+,○ | 38.6 ± 0.8 * | 41.8 ± 1.1 + | 47.3 ± 1.2 |
| Globulins of blood serum, g/L | 29.4 ± 0.9 | 36.9 ± 1.5 *,+ | 28.8 ± 1.6 ○ | 30.7 ± 1.4 | 30.9 ± 0.9 | 32.1 ± 1.2 |
| A/G index | 1.6 ± 0.06 | 1.1 ± 0.05 *,+ | 1.5 ± 0.1 +,○ | 1.3 ± 0.04 * | 1.4 ± 0.1 | 1.5 ± 0.1 |
| AST activity in blood serum, mM/h × L | 378.5 ± 25.7 | 275.0 ± 25.2 * | 279.4 ± 24.6 * | 279.0 ± 18.4 * | 338.8 ± 43.5 | 305.8 ± 18.5 * |
| ALT activity in blood serum, mM/h × L | 75.8 ± 4.8 | 54.7 ± 4.7 * | 55.5 ± 3.3 * | 50.5 ± 3.4 * | 62.3 ± 6.3 | 61.0 ± 2.9 * |
| De Ritis coefficient | 5.01 ± 0.2 | 5.04 ± 0.2 | 4.97 ± 0.2 | 5.68 ± 0.4 | 5.37 ± 0.3 | 5.09 ± 0.3 |
| SH-groups in blood serum, µmol/L | 14.9 ± 0.5 | 18.0 ± 1.4 | 15.7 ± 0.9 | 16.6 ± 1.8 | 12.9 ± 1.7 | 14.9 ± 1.3 |
| Uric acid in blood serum, µmol/L | 157.0 ± 11.8 | 116.6 ± 12.2 * | 112.5 ± 11.9 * | 119.3 ± 7.9 * | 143.3 ± 15.9 | 124.1 ± 6.7 * |
| Urea in blood serum, mmol/L | 5.4 ± 0.5 | 5.07 ± 0.6 | 4.9 ± 0.7 | 4.6 ± 0.5 | 5.3 ± 0.5 | 5.8 ± 0.5 |
| Activity of γ-glutamintransferase in blood serum, nmol/(s × L) | 10.6 ± 0.9 | 8.8 ± 0.8 | 9.3 ± 1.3 | 8.1 ± 0.5* | 9.05 ± 1.02 | 12.6 ± 1.3 |
| Creatinine in blood serum, µmol/L | 48.4 ± 1.9 | 44.6 ± 0.9 | 46.4 ± 0.9 | 44.3 ± 1.5 | 44.2 ± 1.1 | 48.3 ± 1.3 |
| Alkaline phosphatase in blood serum, nmol/(s × L) | 110.7 ± 7.9 | 131.3 ± 8.9 | 124.8 ± 4.4 | 115.2 ± 6.2 | 115.9 ± 8.7 | 104.3 ± 10.9 |
| Catalase in blood serum, µmol/L | 1.6 ± 0.1 | 0.9 ± 0.2 * | 1.1 ± 0.1 * | 0.96 ± 0.2 * | 1.35 ± 0.1 | 1.6 ± 0.1 |
| Reduced glutathione in the blood hemolysate, µmol/L | 22.6 ± 1.9 | 18.4 ± 1.1 | 16.8 ± 1.6 * | 22.1 ± 2.6 | 20.5 ± 1.1 | 17.8 ± 1.7 |
| Ceruloplasmin in blood serum, mg/% | 71.2 ± 2.9 | 98.3 ± 6.28 * | 100.8 ± 6.3 * | 101.3 ± 5.0 * | 121.6 ± 9.6 | 75.6 ± 4.5 |
| MDA in blood serum, nmol/L | 5.21 ± 0.1 | 4.5 ± 0.2 * | 4.9 ± 0.2 | 4.55 ± 0.2 * | 4.49 ± 0.2 | 4.92 ± 0.3 |
| Thyrotropic hormone of hypophysis in blood serum, МE/L | 1.15 ± 0.2 | 1.2 ± 0.2 | 1.7 ± 0.4 | 1.5 ± 0.3 | 0.96 ± 0.4 | 1.0 ± 0.2 |
| Thyroxin in blood serum, pmol/L | 6.7 ± 0.6 | 3.8 ± 0.3 *,+ | 4.8 ± 0.5 * | 4.7 ± 0.4 * | 4.6 ± 0.4 | 4.8 ± 0.2 * |
| Triiodothyronine in blood serum, pmol/L | 12.8 ± 0.9 | 14.8 ± 1.6 | 13.7 ± 1.0 | 13.7 ± 0.7 | 13.2 ± 0.7 | 11.2 ± 0.6 |
| Diuresis, mL | 32.7 ± 1.8 | 30.0 ± 3.1 + | 34.7 ± 3.5 + | 17.9 ± 2.9 * | 30.2 ± 2.7+ | 31.2 ± 4.5 |
| Urine relative density | 1.017 ± 0.001 | 1.017 ± 0.002 + | 1.016 ± 0.001 + | 1.023 ± 0.001 * | 1.019 ± 0.001 + | 1.019 ± 0.001 |
| Protein in urine, g /L | 0.13 ± 0.02 | 0.15 ± 0.01 | 0.11 ± 0.01 +,○ | 0.19 ± 0.04 | 0.16 ± 0.03 | 0.13 ± 0.01 |
| Urea in urine, mmol/L | 146.8 ± 8.4 | 154.6 ± 8.9 | 143.3 ± 9.1 | 183.6 ± 15.3 | 147.4 ± 8.4 | 134.2 ± 7.6 |
| Uric acid in urine, µmol/L | 91.8 ± 8.9 | 138.3 ± 11.4 * | 98.4 ± 6.0 +,○ | 166.0 ± 19.1 * | 116.6 ± 11.9 | 89.8 ± 6.2 |
| Creatinine in urine, mmol/L | 1.09 ± 0.1 | 1.4 ± 0.1 * | 1.13 ± 0.08 + | 1.8 ± 0.2 * | 1.2 ± 0.1 + | 1.2 ± 0.1 |
| Endogenous creatinine clearance, mL/min | 0.76 ± 0.03 | 0.90 ± 0.03 *,+ | 0.84 ± 0.05 | 0.66 ± 0.07 | 0.78 ± 0.04 | 0.72 ± 0.05 |
| δ–ALA in urine, µmol/L | 6.7 ± 1.6 | 8.27 ± 1.8 | 11.9 ± 1.8 | 9.0 ± 1.5 | 6.2 ± 0.6 | 8.4 ± 1.3 |
| δ–ALA in urine, µmol/day | 0.23 ± 0.07 | 0.29 ± 0.05 | 0.34 ± 0.08 | 0.54 ± 0.13 | 0.22 ± 0.02 + | 0.25 ± 0.08 |
* statistically significant difference from the control group; + from the group given NiO-NPs + Mn3O4-NPs (without the BPC); ○ from the group given Mn3O4-NPs; (p < 0.05 by Student’s t-test with Bonferroni correction).
Figure 2Kidney of a control rat (proximal convoluted tubules with an intact brush border). Periodic Acid Shiff (PAS) stain, magnification ×400.
Figure 3Kidney of a rat exposed to nanoparticles of NiO and Mn3O4 together. Marked degenerative and necrobiotic changes of tubular epithelial cells up to their disappearance; partial destruction of the brush border. PAS stain, magnification ×400.
Figure 4Kidney of a rat exposed to nanoparticles of NiO and Mn3O4 together against the background BPC administration. Marked alleviation of tubular damage (compare with Figure 2 and Figure 3). PAS stain, magnification ×400.
Morphometric indices for tubular epithelium damage in the kidneys of rats after repeated intraperitoneal injections of NiO or Mn3O4 nanoparticles, together or separately, and of their combination with background oral administration of the BPC (X ± s.e.).
| Groups of Rats Given | Brush Border Loss (% Lengthwise) | Epithelial Desquamation (% Lengthwise) |
|---|---|---|
| Water (control) (4 rats) | 5.44 ± 0.9 | 0.00 ± 0 |
| NiO-NPs (4 rats) | 10.3 ± 1.7 * | 0.48 ± 0.36 |
| Mn3O4-NPs (4 rats) | 9.02 ± 1.17 * | 0.28 ± 0.32 + |
| NiO-NPs + Mn3O4-NPs (4 rats) | 12.33 ± 2.3 * | 2.43 ± 1.0 * |
| NiO-NPs + Mn3O4-NPs + BPC (4 rats) | 7.08 ± 1.7 | 0.00 ± 0 + |
* statistically significant difference from the control group; + from the group given NiO-NPs + Mn3O4-NPs (without the BPC); (p < 0.05 by Student’s t-test with Bonferroni correction).
Morphometric indices for the state of rat’s liver and spleen after repeated intraperitoneal injections of NiO or Mn3O4 nanoparticles, together or separately, and of their combination with background oral administration of the BPC (X ± s.e.).
| Indices | Groups of Rats (4 Rats) | ||||
|---|---|---|---|---|---|
| Control | NiO-NPs | Mn3O4-NPs | NiO-NPs + Mn3O4-NPs | Nio-NPs + MN3O4-NPs + BPC | |
| Liver | |||||
| Akaryotic hepatocytes per 100 liver cells | 2.73 ± 0.28 | 7.93 ± 0.51 *,+ | 6.03 ± 0.42 * | 5.43 ± 0.41 * | 3.38 ± 0.34 + |
| Binucleated hepatocytes per 100 liver cells | 17.15 ± 0.66 | 14.33 ± 0.63 + | 18.03 ± 0.60 | 18.40 ± 0.92 | 16.20 ± 0.72 |
| Kupffer cells per 100 liver cells | 11.25 ± 0.55 | 10.20 ± 0.63 + | 12.75 ± 0.45 *,+ | 16.30 ± 1.22 * | 12.2 ± 0.7 + |
| Spleen | |||||
| Red pulp to white pulp ratio | 8.3 ± 1.4 | 4.5 ± 0.9 * | 5.2 ± 1.3 | 3.6 ± 0.4 * | 6.2 ± 1.3 + |
| Number of brown pigment micro aggregates per square of the avtandilov’s grid | 0 | 2.5 ± 0.2 ○ | 6.4 ± 0.3 *,+ | 10.4 ± 0.4 * | 5.9 ± 0.2 *,+ |
* statistically significant difference from the control group; + from the group given NiO-NPs + Mn3O4-NPs (without the BPC); ○ from the group given Mn3O4-NPs; (p < 0.05 by Student’s t-test with Bonferroni correction).
Figure 5The brain of a control rat, hippocampus (CA1). Hematoxylin and eosin stain, magnification ×400. The neuron nuclei are predominantly spherical with well-visible eosinophilic granulosity, and notable nucleoli in the center.
Figure 6The brain of a rat exposed to nanoparticles of NiO and Mn3O4 together; hippocampus (CA1). Hematoxylin and eosin stain, magnification ×400. A lot of neurons with marked degenerative changes or pycnosis; in some nuclei the nucleolus is displaced or absent.
Morphometric indices for the state of the rat’s brain after repeated intraperitoneal injections of NiO or Mn3O4 nanoparticles, together or separately, and of their combination with background oral administration of the BPC (X ± s.e.).
| Neurons (%) | Control (4 Rats) | Mn3O4-NPs (4 Rats) | NiO-NPs (4 Rats) | NiO-NPs + Mn3O4-NPs (4 Rats) | NiO-NPs + Mn3O4-NPs and BPC (4 Rats) |
|---|---|---|---|---|---|
| Nucleus caudatus | |||||
| Without a nucleolus | 30.50 ± 2.77 | 69.90 ± 1.79 *,+ | 47.36 ± 2.45 *,+ | 60.30 ± 2.26 * | 37.15 ± 2.89 + |
| With a distinct centrally located nucleolus | 25.12 ± 1.16 | 9.33 ± 0.90 *,+ | 17.00 ± 1.04 *,+ | 12.35 ± 0.95 * | 23.28 ± 1.09 + |
| Hippocampus (CA 1) | |||||
| Without a nucleolus | 30.50 ± 2.30 | 70.45 ± 2.31 * | 35.8 ± 2.21 + | 70.40 ± 3.75 * | 41.30 ± 2.14 *,+ |
| With a distinct centrally located nucleolus | 46.4 ± 2.92 | 13.4 ± 1.51 * | 31.6 ± 1.75 *,+ | 11.0 ± 1.13 * | 30.5 ± 1.96 *,+ |
* statistically significant difference from the control group; + from the group given NiO-NPs + Mn3O4-NPs (without the BPC); (p < 0.05 by Student’s t-test with Bonferroni correction).
Figure 7The brain of a rat exposed to nanoparticles of NiO and Mn3O4 together against the background BPC administration; hippocampus (CA1). Hematoxylin and eosin stain, magnification ×400. Marked alleviation of neuronal damage (compare with Figure 5 and Figure 6).
The coefficient of genomic DNA fragmentation in the blood nucleated cells of rats after repeated intraperitoneal injections of NiO or Mn3O4 nanoparticles, together or separately, and of their combination with background oral administration of the BPC (X ± s.e.).
| Control (6 Rats) | Mn3O4-NPs (6 Rats) | NiO-NPs (6 Rats) | NiO-NPs + Mn3O4-NPs (6 Rats) | NiO-NPs + Mn3O4-NPs and BPC (6 Rats) | BPC (6 Rats) |
|---|---|---|---|---|---|
| 0.42 ± 0.00 | 0.51 ± 0.01 * | 0.51 ± 0.01 * | 0.50 ± 0.01 * | 0.45 ± 0.01 *,+ | 0.41 ± 0.01 |
* statistically significant difference from the control group; + from the group given NiO-NPs + Mn3O4-NPs (without the BPC); (p < 0.05 by Student’s t-test with Bonferroni correction).
Figure 8SEM images of NiO (left) and Mn3O4 (right) nanoparticles in suspension obtained by scanning electron microscopy.
Figure 9Characteristics of nickel oxide NPs produced by laser ablation. (A) Raman spectrum; (B) size distribution function obtained by statistical processing of SEM NPs images.
Figure 10Characteristics of manganese oxide nanoparticles produced by laser ablation. (A) Raman spectrum; (B) size distribution function obtained by statistical processing of SEM images of NPs.
Doses and the mode of administration of the bioprotectors tested in our experiment.
| Bioprotectors | Estimated Dosage and the Mode of Administration |
|---|---|
| Apple pectin | 1 g/kg (added to the fodder) |
| Sodium glutamate | 160 mg per rat (as a 1.5% drink instead of water) |
| Glycine | 12 mg per rat (added to the fodder) |
| 30 mg per rat (added to the fodder) | |
| Vitamin C | 4.4 mg per rat (added to the fodder) |
| Vitamin E | 0.84 mg per rat (added to the fodder) |
| Selenium | 4.0 mcg per rat (added to the fodder) |
| Commercial fish oil rich in vitamin A and omega 3 rich PUFA | 1 drop per rat (sublingually) |
| Potassium iodide | 4.0 mcg per rat (added to the fodder) |